Sydney School of Medicine (Central Clinical School), Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
Drug and Alcohol Services, South Eastern Sydney Local Health District, NSW, Australia.
Addiction. 2021 May;116(5):1245-1255. doi: 10.1111/add.15331. Epub 2021 Jan 4.
The Australian Treatment Outcomes Profile (ATOP) is a brief instrument measuring recent substance use, risk profile and general health and wellbeing among clients attending alcohol and other drug (AoD) treatment services. This study evaluates the ATOP for concurrent validity, inter-rater and test-re-test reliability among alcohol and opioid treatment groups.
For concurrent validity and inter-rater reliability, participants completed an ATOP with a clinician and an ATOP plus standardized questionnaires (time-line follow-back, Opiate Treatment Index, Kessler-10, 12-item Short Form Survey, World Health Organization Quality of Life-BREF, Personal Wellbeing Index) with a researcher within 3 days. For test-re-test reliability, participants completed two ATOPs with a researcher within a 3-day interval.
Outpatient AoD treatment centres in Australia.
For testing concurrent validity and inter-rater reliability, 278 participants were recruited by advertisements in waiting-rooms or clinician invitation during 2016 to 2018. A further 94 participants were recruited to examine test-re-test reliability.
Statistical tests used for concurrent validity and test-re-test reliability were Pearson's and Spearman's rank order correlations for continuous variables, and Cohen's κ for nominal variables. Inter-rater reliability was assessed using Krippendorf's α.
Most Australian Treatment Outcomes Profile items returned excellent or moderate validity and reliability. For the main substances used-alcohol, cannabis and benzodiazepines-concurrent validity, inter-rater reliability and test-re-test reliability all reached excellent or good agreement (0.72-0.96). Psychological health, physical health and quality of life showed fair to strong agreement with their comparator scales (0.47-0.85).
The Australian Treatment Outcomes Profile is a validated and reliable instrument for assessing recent substance use and clinical risk, health and welfare among alcohol and opioid clients in alcohol and other drug treatment settings. Its ability to reliably measure complex constructs, such as psychological and physical health, against longer scales makes it suitable for integration into routine clinical care, enabling regular monitoring of patient outcomes and safety parameters.
澳大利亚治疗结果概况（ATOP）是一种简短的工具，用于衡量接受酒精和其他药物（AoD）治疗服务的患者最近的物质使用情况、风险概况以及整体健康和福利。本研究评估了 ATOP 在酒精和阿片类药物治疗组中的同时效度、评分者间信度和重测信度。
为了评估同时效度和评分者间信度，参与者在 3 天内与临床医生完成 ATOP 并与研究人员完成 ATOP 加标准化问卷（时间线随访、阿片类药物治疗指数、Kessler-10、12 项简短健康调查、世界卫生组织生活质量-BREF、个人幸福感指数）。为了评估重测信度，参与者在 3 天的间隔内与研究人员完成了两次 ATOP。
澳大利亚的门诊 AoD 治疗中心。
为了测试同时效度和评分者间信度，2016 年至 2018 年期间，通过在候诊室的广告或临床医生邀请招募了 278 名参与者。为了检验重测信度，招募了另外 94 名参与者。
用于同时效度和重测信度的统计检验包括连续变量的皮尔逊和斯皮尔曼等级相关，以及名义变量的科恩κ。评分者间信度采用克里普多夫的α评估。
大多数澳大利亚治疗结果概况项目具有极好或中度的有效性和可靠性。对于主要使用的物质（酒精、大麻和苯二氮䓬类药物），同时效度、评分者间信度和重测信度均达到极好或良好的一致性（0.72-0.96）。心理健康、身体健康和生活质量与他们的比较量表显示出公平到强烈的一致性（0.47-0.85）。
澳大利亚治疗结果概况是一种经过验证和可靠的工具，可用于评估酒精和阿片类药物治疗环境中酒精和阿片类药物患者最近的物质使用情况和临床风险、健康和福利。它能够可靠地测量复杂的结构，如心理健康和身体健康，与较长的量表相比，使其适合纳入常规临床护理，能够定期监测患者的结果和安全参数。
